CXCL1 and glioblastoma: These results indicate that targeting the MDK signaling pathway can inhibit the polarization of macrophages towards the immune suppressive M2 subtype and the secretion of the immune suppressive cytokine CXCL1, reverse the formation of the immune suppressive microenvironment, and slow down the malignant progression of GBM (Fig. 6F).